DK132287A - Anvendelse af n-substitueret isobutyramid i racemisk (r,s)-form eller i venstredrejende optisk aktiv (s)-form eller et salt heraf til fremstilling af et laegemiddel mod obesitet - Google Patents

Anvendelse af n-substitueret isobutyramid i racemisk (r,s)-form eller i venstredrejende optisk aktiv (s)-form eller et salt heraf til fremstilling af et laegemiddel mod obesitet

Info

Publication number
DK132287A
DK132287A DK132287A DK132287A DK132287A DK 132287 A DK132287 A DK 132287A DK 132287 A DK132287 A DK 132287A DK 132287 A DK132287 A DK 132287A DK 132287 A DK132287 A DK 132287A
Authority
DK
Denmark
Prior art keywords
isobutyramide
racemic
substituted
salt
preparation
Prior art date
Application number
DK132287A
Other languages
English (en)
Other versions
DK132287D0 (da
Inventor
Brian Roy Holloway
Ralph Howe
Balbir Singh Rao
Donald Stribling
Original Assignee
Ici Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ici Plc filed Critical Ici Plc
Publication of DK132287D0 publication Critical patent/DK132287D0/da
Publication of DK132287A publication Critical patent/DK132287A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK132287A 1986-03-25 1987-03-13 Anvendelse af n-substitueret isobutyramid i racemisk (r,s)-form eller i venstredrejende optisk aktiv (s)-form eller et salt heraf til fremstilling af et laegemiddel mod obesitet DK132287A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868607312A GB8607312D0 (en) 1986-03-25 1986-03-25 Therapeutic agents

Publications (2)

Publication Number Publication Date
DK132287D0 DK132287D0 (da) 1987-03-13
DK132287A true DK132287A (da) 1987-09-26

Family

ID=10595167

Family Applications (1)

Application Number Title Priority Date Filing Date
DK132287A DK132287A (da) 1986-03-25 1987-03-13 Anvendelse af n-substitueret isobutyramid i racemisk (r,s)-form eller i venstredrejende optisk aktiv (s)-form eller et salt heraf til fremstilling af et laegemiddel mod obesitet

Country Status (6)

Country Link
US (1) US4937267A (da)
EP (1) EP0244080A3 (da)
JP (1) JPS62230722A (da)
DE (1) DE3709621A1 (da)
DK (1) DK132287A (da)
GB (2) GB8607312D0 (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE93138T1 (de) † 1990-02-09 1993-09-15 Upjohn Co Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
US5356913A (en) * 1990-02-09 1994-10-18 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
EP1035115B1 (en) 1999-02-24 2004-09-29 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
IL156445A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
NZ542090A (en) * 2001-01-26 2006-09-29 Schering Corp Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
EP1385548B1 (en) * 2001-01-26 2007-05-23 Schering Corporation Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
KR20070120617A (ko) * 2001-01-26 2007-12-24 쉐링 코포레이션 치환된 아제티딘온 화합물을 포함하는 약제학적 조성물
TW200840563A (en) * 2001-01-26 2008-10-16 Schering Corp Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(S) and treatments for vascular indications
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
PT1363668E (pt) * 2001-01-26 2007-11-07 Schering Corp Combinaçoes de sequestrante(s) de ácidos biliares e inibidor(es) de absorção de esterol e tratamento de indicações vasculares
WO2002096415A2 (en) * 2001-05-25 2002-12-05 Schering Corporation Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
WO2003013571A1 (en) * 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
DE60229406D1 (de) * 2001-09-21 2008-11-27 Schering Corp Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
EP1429756B1 (en) * 2001-09-21 2006-11-22 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
CA2504916A1 (en) * 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
DE602004018617D1 (de) 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
WO2004081004A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
WO2004081002A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7288658B2 (en) 2003-07-15 2007-10-30 Hoffmann-La Roche Inc. Process for preparation of pyridine derivatives
WO2005046797A2 (en) * 2003-11-05 2005-05-26 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
ATE453384T1 (de) 2005-09-23 2010-01-15 Hoffmann La Roche Neue dosierformulierung
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
US9044606B2 (en) 2010-01-22 2015-06-02 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue using electrical energy
US8476227B2 (en) 2010-01-22 2013-07-02 Ethicon Endo-Surgery, Inc. Methods of activating a melanocortin-4 receptor pathway in obese subjects
US10080884B2 (en) 2014-12-29 2018-09-25 Ethicon Llc Methods and devices for activating brown adipose tissue using electrical energy
US10092738B2 (en) 2014-12-29 2018-10-09 Ethicon Llc Methods and devices for inhibiting nerves when activating brown adipose tissue

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3961072A (en) * 1969-12-17 1976-06-01 Pfizer Inc. Phenoxypropanolamine therapeutic agents
GB1455116A (en) * 1972-12-15 1976-11-10 Ici Ltd Pharmaceutical compositions
US4083992A (en) * 1972-12-15 1978-04-11 Imperial Chemical Industries Limited Alkanolamine derivatives
GB1468156A (en) * 1973-07-19 1977-03-23 Ici Ltd Phenylethylamine derivatives
GB1458392A (en) * 1973-11-09 1976-12-15 Ici Ltd Optically-active 1-aryloxy-2,3-epoxypropane derivatives
FI65987C (fi) * 1973-12-12 1984-08-10 Ici Ltd Foerfarande foer framstaellning av nya terapeutiskt anvaendbara alkanolaminderivat
ATE1899T1 (de) * 1979-06-16 1982-12-15 Beecham Group Plc Sekundaere amine, ihre herstellung und verwendung in pharmazeutischen zusammensetzungen.
US4618624A (en) * 1981-12-02 1986-10-21 American Cyanamid Company 3-amino-4-hydroxy(or alkoxy)phenethanolamine derivatives and pharmacologically-acceptable acid addition salts thereof for increasing the growth rate and/or improving the lean meat to fat ratio of warm-blooded animals
EP0085514A3 (en) * 1982-01-28 1984-02-29 Beecham Group Plc Compositions comprising a beta-antagonist and a beta-agonist, their preparation, and their use in treating obese humans and animals

Also Published As

Publication number Publication date
EP0244080A2 (en) 1987-11-04
DK132287D0 (da) 1987-03-13
GB2188234B (en) 1991-01-02
GB8706946D0 (en) 1987-04-29
GB2188234A (en) 1987-09-30
DE3709621A1 (de) 1987-10-08
JPS62230722A (ja) 1987-10-09
EP0244080A3 (en) 1990-05-16
US4937267A (en) 1990-06-26
GB8607312D0 (en) 1986-04-30

Similar Documents

Publication Publication Date Title
DK132287D0 (da) Anvendelse af n-substitueret isobutyramid i racemisk (r,s)-form eller i venstredrejende optisk aktiv (s)-form eller et salt heraf til fremstilling af et laegemiddel mod obesitet
DK368480A (da) Optisk aktive 1,4-dihydropyridiner fremgangsmaader til deres fremstilling og deres anvendelse som laegemidler
DK161668C (da) Anvendelse af phenyleddikesyrederivater til fremstillingen af et farmaceutisk middel til behandling af eller forebyggelse mod oejenbetaendelse
DK584089D0 (da) Quinuclidiner, deres anvendelse som laegemiddel og fremgangsmaade til deres fremstilling
DE3689571D1 (de) Halogenhaltige, optisch aktive Flüssigkristallverbindung und dieselbe enthaltende Flüssigkristallzusammensetzung.
NO812933L (no) Aminosyrederivater, fremgangsmaate til deres fremstilling, midler som inneholder forbindelsene samt deres anvendelse
DK349387D0 (da) Nitrofuranderivater samt fremgangsmaade til fremstilling deraf og anvendelse af forbindelserne som laegemiddel
DK143284A (da) Thiazolinderivater, deres fremstilling og anvendelse som laegemiddel
DK160981C (da) Arylsulfonylurinstof-derivater, fremgangsmaade til fremstilling deraf, anvendelse af disse som terapeutisk og antineoplastisk middel samt farmaceutiske midler indeholdende saadanne derivater
DK368088D0 (da) 6,7-dihydropyrazolooe1,5-aaaoe1,3,5aatriazin-2-sulfonsyreamider, fremgangsmaader til fremstilling heraf samt deres anvendelse som middel med herbizid og plantevaekstregulerende virkning
DK539087D0 (da) 4,5-dihydro- og 4,5,6,7-tetrahydro-pyrazolooe1,5-aaapyrimidiner, fremgangsmaader til deres fremstilling samt deres anvendelse som laegemidler
NO890187D0 (no) 2-(3,4-dihydroksyfenyl)etylaminer, deres fremstilling og anvendelse som farmasoeytika.
NO884005L (no) Fluorerte derivater av aminosyrer saerlig for bruk som overflateaktive midler.
NO874786D0 (no) Optisk aktive gyrasehemmere, deres fremstilling og anvendelse som antibiotika.
NO860907L (no) Heterocykliske sulfider og deres anvendelse som immunmodulatorer.
DK166210C (da) Krystallinske cephalosporin-hydrohalogenidsalte, fremgangsmaade til fremstilling deraf samt deres anvendelse som laegemidler
DK284688D0 (da) Beta-lactam-forbindelser, deres fremstilling og anvendelse som laegemidler
DK163639C (da) Synergistisk farmaceutisk blanding af vaevsplasminogenaktivator og et prostaglandin, farmaceutisk praeparat indeholdende blandingen samt anvendelse af blandingen til fremstilling af et laegemiddel mod blodpropper
NO875466L (no) Komplekser av vismut- eller antimonhalogenider og aminer,fremgangsmaate for fremstilling derav, samt polymerer inneholdende kompleksene som flammehemmende middel.
DK300583D0 (da) Racemiske eller optisk aktive eburnanoximderivater eller syreadditionssalte deraf, deres fremstilling og anvendelse
DK131187A (da) Anvendelse af aminosubstituerede benzoesyrer som laegemidler mod diarre og laegemidler paa grundlag af disse forbindelser
DK586284D0 (da) Quinoloncarboxylsyre-derivater, fremgangsmaade til fremstilling deraf samt anvendelse af saadanne derivater som laegemiddel
DK513188D0 (da) Aminosyreestre, deres fremstilling og anvendelse som laegemidler
DK176183D0 (da) Beta-lactam-antibiotika, fremgangsmade til fremstilling deraf samt deres anvendelse som laegemiddel
DK299983A (da) Racemiske eller optisk aktive apovincaminsyrederivater eller farmaceutisk aktive syreadditionssalte deraf, deres fremstilling og anvendelse

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment